Antiretroviral therapy 2006: Pharmacology, applications, and special situations

Archives of Pharmacal Research

Volumn 29, Issue 6, 2006, Pages 431-458

  Samuel, Rafik ^a,b   Bettiker, Robert ^a   Suh, Byungse ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

Antiretroviral therapy; CD4 count; HIV; Non nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Protease inhibitors; Viral load

Indexed keywords

EID: 33746108186     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02969415     Document Type: Review

References (266)

1. Aarnoutse, R. E., Grintjes, K. J., Telgt, D. S., Stek, M., Hugen, P. W., Reiss, P., Koopmans, P. P., Hekster, Y. A., and Burger, D. M., The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin. Pharmacol. Ther., 71, 57-67 (2002).
2. Acosta, E. P., Page, L. M., and Fletcher, C. V., Clinical pharmacokinetics of zidovudine. Clin. Pharmacokinet., 30, 251-262 (1996).
3. Adkins, J. C. and Noble, S., Efavirenz. Drugs, 56, 1055-1064 (1998).
4. Alberti, A., Clumeck, N., Collins, S., Gerlich, W., Lundgren, J., Palu, G., Reiss, P., Thiebaut, R., Weiland, O., Yazdanpanah, Y., and Zeuzem, S., Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J. Hepatol., 42, 615-624 (2005).
5. American College of Obstetricians and Gynecologists Committee Opinion. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Number 234. Washington DC: The American College of Obstetricians and Gynecologists, May (2000).
6. Antoniou, T. and Tseng, A. L., Interactions between recreational drugs and antiretroviral agents. Ann. Pharmacother., 36, 1598-1613 (2002).
7. Arvieux, C. and Tribut, O., Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs, 65, 633-659 (2005).
8. Bartlett, J. A., Zalcitabine, p. 49-59. In Dolin R, Masur H, and Saag MS (ed), AIDS Therapy. Churchill Livingstone, Philadelphia, (1999).
9. Baxter, J. D., Mayers, D. L., Wentworth, D. N., Neaton, J. D., Hoover, M. L., Winters, M. A., Mannheimer, S. B., Thompson, M. A., Abrams, D. I., Brizz, B. J., Ioannidis, J. P., and Merigan, T. C., A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS., 14, F83-93 (2000).
10. Benhamou, Y., Bochet, M., Thibault, V., Di Martino, V., Caumes, E., Bricaire, F., Opolon, P., Katlama, C., and Poynard T., Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology, 30, 1302-1306 (1999).
11. Benhamou, Y., Bochet, M., Thibault, V., Calvez, V., Fievet, M. H., Vig, P., Gibbs, C. S., Brosgart, C., Fry, J., Namini, H., Katlama, C., and Poynard T., Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet., 358, 718-723 (2001).
12. Benhamou, Y., Tubiana, R., and Thibault, V., Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N. Engl. J. Med., 348, 177-178 (2003).
13. Bergshoeff, A., Burger, D., Verweij, C., Farrelly, L., Flynn, J., Le Prevost, M., Walker, S., Novelli, V., Lyall, H., Khoo, S., and Gibb, D., for the PENTA-13 Study Group. Plasma pharmacokinetics of once-versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir. Ther., 10, 239-246 (2005)
14. Bodsworth, N. J., Cooper, D. A., and Donovan B., The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J. Infect. Dis., 163, 1138-1140 (1991).
15. Bonacini, M., Lin, H. J., and Hollinger, F. B., Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J. AIDS., 26, 340-344 (2001).
16. Bonnet, F., Bonarek, M., Morlat, P., Mercie, P., Dupon, M., Gemain, M. C., Malvy, D., Bernard, N., Pellegrin, J. L., and Beylot, J., Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin. Infect. Dis., 36, 1324-1328 (2003).
17. Bossi, P., Colin, D., Bricaire, F., and Caumes, E., Hypersensitivity syndrome associated with efavirenz therapy. Clin. Infect. Dis., 30, 227-228 (2000).
18. Bozzette, S. A., Ake, C. F., Tam, H. K., Chang, S. W., and Louis, T. A., Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med., 348, 702-710 (2003).
19. Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A., and Koopmans, P. P., Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS., 12, 1735-1744 (1998).
20. Bristol-Myers Squibb. Important drug warning: January 5, 2001. Rockville, Md.: Food and Drug Administration, 2001. (Accessed February 15 2006, at http://www.fda.gov/medwatch/safety/2001/zerit&videx_letter.htm.
21. Brook, M. G., McDonald, J. A., Karayiannis, P., Caruso, L., Forster, G., Harris, J. R., and Thomas, H. C., Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut., 30, 1116-1122 (1989).
22. Brunelle, M. N., Jacquard, A. C., Pichoud, C., Durantel, D., Carrouee-Durantel, S., Villeneuve, J. P., Trepo, C., and Zoulim, F., Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology, 41, 1391-1398 (2005).
23. Buti, M. and Esteban, R. Drugs in Development for Hepatitis B. Drugs., 65, 1451-1460 (2005).
24. CDC. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. Recommendations from the US Department of Health and Human Services. MMWR, 54, RR-2 (2005).
25. CDC. Treating Opportunistic Infections among HIV-infected adults and adolescents. Recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR, 53, RR-15 (2004).
26. CDC. Updated US Public health service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR, 54, RR-9 (2005).
27. Cameron, D. W., Japour, A. J., Xu, Y., Hsu, A., Mellors, J., Farthing, C., Cohen, C., Poretz, D., Markowitz, M., Follansbee, S., Angel, J. B., McMahon, D., Ho, D., Devanarayan, V., Rode, R., Salgo, M., Kempf, D. J., Granneman, R., Leonard, J. M., and Sun, E., Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS., 13, 213-224 (1999).
28. Campo, R. E., Lalanne, R., Tanner, T. J., Jayaweera, D. T., Rodriguez, A. E., Fontaine, L., and Kolber, M. A., Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS., 19, 447-449 (2005).
29. Carr, A., Samaras, K. Chisholm, D. J., and Cooper, D. A., Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet., 352, 1881-1883 (1998).
30. Cervia, J. S. and Smith, M. A., Enfuvirtide (T-20): A novel human immunodeficiency virus type 1 fusion inhibitor. Clin. Infect. Dis., 37, 1102-1106 (2003).
31. Chamot, E., Hirschel, B., Wintsch, J., Robert, C. F., Gabriel, V., Deglon, J. J., Yerly, S., and Perrin, L., Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS., 4, 1275-1277 (1990).
32. Chapman, T. M., Plosker, G. L., and Perry, C. M., Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs., 64, 2101-2124 (2004).
33. Clavel, F. and Hance, A. J., HIV Drug Resistance. N. Engl. J. Med., 350, 1023-1035 (2004).
34. Clevenbergh, P., Corcostegui, M., Gerard, D., Hieronimus, S., Mondain, V., Chichmanian, R. M., Sadoul, J. L., and Dellamonica, P., Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen. J. Infection., 44, 194-195 (2002).
35. Cohen, C. J., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, S., Nadler, J., Verbiest, W., Hertogs, K., Ames, M., Rinehart, A. R., Graham, N. M., and the VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS., 16, 579-588 (2002).
36. Colfax, G. N., Buchbinder, S. P., Corneliss, P. G., Vittinghoff, E., Mayer, K., and Celum, C., Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS., 16, 1529-1535 (2002).
37. Colin, J. F., Cazals-Hatem, D., Loriot, M. A., Martinot-Peignoux, M., Pham, B. N., Auperin, A., Degott, C., Benhamou, J. P., Erlinger, S., Valla, D., and Marcellin P. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology, 29, 1306-1310 (1999)
38. Collier, A. C., Coombs, R. W., Schoenffeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., Friedman, H. M., Merigan, T. C., Reichman, R. C., Hooper, C., and Corey, L., Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med., 334, 1011-1017 (1996).
39. Connor, E. M., Sperling, R. S., Gelber, R., and Kiselev, P., Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med., 331, 1173-1180 (1994).
40. Cooper, C. L., van Heeswijk, R. P. G., Gallicano, K., and Cameron, D. W., A Review of Low-Dose Ritonavir in Protease Inhibitor Combination Therapy. Clin. Infect. Dis., 36, 1585-1592 (2003).
41. Cooper, E. R., Charurat, M., Mofenson, L., Hanson, I. C., Pitt, J., Diaz, C., Hayani, K., Handelsman, E., Smeriglio, V., Hoff, R., Blattner, W., and the Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr., 29, 484-494 (2002).
42. Croom, K. F. and Keam, S. J., Tipranavir, A ritonavir boosted protease inhibitor. Drug, 65, 1669-1677 (2005).
43. D'Aquila, R. M., Hughes, M. D., Johnson, V. A., Fischl, M. A., Sommadossi, J. P., Liou, S. -H., Timpone, J., Myers, M., Basgoz, N., Niu, M., and Hirsch, M. S., Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann. Intern. Med., 124, 1019-1030 (1996).
44. Darby, S. C., Ewart, D. W., Giangrande, P. L., Spooner, R. J., Rizza, C. R., Dusheiko, G. M., Lee, C. A., Ludlam, C. A., and Preston, F. E., Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet., 350, 1425-1431 (1997).
45. Deeks, S. G., Wrin, T., Liegler, T., Hoh, R., Hayden, M., Barbour, J. D., Hellmann, N. S., Petropoulos, C. J., McCune, J. M., Hellerstein, M. K., and Grant, R. M., Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med., 344, 472-480 (2001).
46. de Franchis, R., Hadengue, A., Lau, G., Lavanchy, D., Lok, A., McIntyre, N., Mele, A., Paumgartner, G., Pietrangelo, A., Rodes, J., Rosenberg, W., Valla, D., and the EASL Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J. Hepatol., 39 (Suppl 1), S3-25 (2003).
47. Demeter, L. M. and Reichman, R. C., Delavirdine, p 97-105. In Dolin R, Masur H, and Saag MS (ed), AIDS Therapy. Churchill Livingstone, Philadelphia. (1999).
48. den Brinker, M., Wit, F. W., Wertheim-van Dillen, P. M., Jurriaans, S., Weel, J., van Leeuwen, R., Pakker, N. G., Reiss, P., Danner, S. A., Weverling, G. J., and Lange, J. M., Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS., 14, 2895-2902 (2000).
49. Detels, R., Munoz, A., McFarlane, G., Kingsley, L. A., Margolick, J. B., Giorgi, J., Schrager, L. K., and Phair, J. P., Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA., 280, 1497-1503 (1998).
50. Dickover, R. E., Garratty, E. M., Herman, S. A., Sim, M. S., Plaeger, S., Boyer, P. J., Keller, M., Deveikis, A., Stiehm, E. R., and Bryson, Y. J., Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA., 275, 599-605 (1996).
51. di Martino, V., Lunel, F., Cadranel, J. F., Hoang, C., Parlier, Y., Le Charpentier, Y., and Opolon, P., Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J. Vir. Hepat., 3, 253-260 (1996).
52. Di Martino, V., Thevenot, T., Boyer, N., Degos, F., and Marcellin, P., Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. Hepatology, 31, 1030-1031 (2000).
53. Di Martino, V., Rufat, P., Boyer, N., Renard, P., Degos, F., Martinot-Peignoux, M., Matheron, S., Le Moing, V., Vachon, F., Degott, C., Valla, D., and Marcellin, P. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology, 34, 1193-1199 (2001).
54. Di Martino, V., Thevenot, T., Colin, J. F., Boyer, N., Martinot, M., Degos, F., Coulaud, J. P., Vilde, J. L., Vachon, F., Degott, C., Valla, D., and Marcellin, P., Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology, 123, 1812-1822 (2002).
55. Dore, G. J., Cooper, D. A., Barrett, C., Goh, L. E., Thakrar, B., and Atkins, M., Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J. Infect. Dis., 180, 607-613 (1999).
56. Dorenbaum, A., Cunningham, C. K., Gelber, R. D., Culnane, M., Mofenson, L., Britto, P., Rekacewicz, C., Newell, M. L., Delfraissy, J. F., Cunningham-Schrader, B., Mirochnick, M., Sullivan, J. L., and the International PACTG 316 Team. Two-dose - intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial. JAMA., 288, 189-198 (2002).
57. Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L., and Lamarre, D., Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol., 70, 3763-3769 (1996).
58. Dragsted, U. B., Gerstoft, J., Pedersen, C., Peters, B., Duran, A., Obel, N., Castagna, A., Cahn, P., Clumeck, N., Bruun, J. N., Benetucci, J., Hill, A., Cassetti, I., Vernazza, P., Youle, M., Fox, Z., Lundgren, J. D., and the MaxCmin1 Trial Group. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J. Infect. Dis., 188, 635-642 (2003).
59. Dube, M. P., Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin. Infect. Dis., 31, 1467-1475 (2000).
60. Dube, M. P. and Sattler, F. R., Metabolic complications of antiretroviral therapies. AIDS Clin. Care., 10, 41-44 (1998).
61. Dube, M. P., Stein, J. H., Aberg, J. A., Fichtenbaum, C. J., Gerber, J. G., Tashima, K. T., Henry, W. K., Currier, J. S., Sprecher, D., and Glesby, M. J., Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis., 37, 613-627 (2003).
62. Durant, J., Clevenbergh, P., Halfon, P., Delgiudice, P., Porsin, S., Simonet, P., Montagne, N., Boucher, C. A., Schapiro, J. M., and Dellamonica, P., Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet., 353, 2195-2199 (1999).
63. Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., and Pau, A. K., Guidelines for Using Antiretroviral Agents Among HIV-Infected Adults and Adolescents. MMWR., 51(RR7), 1-64 (2002).
64. El-Sadr, W. and Neaton, J., Episodic CD4-guided use of antiretroviral therapy is inferior to continuous therapy: results of the SMART study. Abstract 106LB Conference on Retroviruses and Opportunistic Infections. Denver, CO. U.S.A., (2006).
65. Eskild, A., Magnus, P., Petersen, G., Sohlberg, C., Jensen, F., Kittelsen, P., and Skaug, K., Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS., 6, 571-574 (1992).
66. Esnouf, R. M., Ren, J., Hopkins, A. L., Ross, C. K., Jones, E. Y., Stammers, D. K., and Stuart, D. I., Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. P. Natl. Acad. Sci. U.S.A., 94, 3984-3989 (1997).
67. The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS., 13, 1377-1385 (1999).
68. Fargioin, S., Fracanzani, A. L., and Valenti, L., Treatment Choices for people infected with HCV. J. Antimicrob. Chemother., 53, 708-712 (2004).
69. Feng, J. Y., Myrick, F. T., Margot, N. A., Mulamba, G. B., Rimsky, L., Borroto-Esoda, K., Selmi, B., and Canard, B., Virologic and enzymatic studies revealing the mechanism of K65R-and Q151m-associated HIV-1 drug resistance towards emtricitabine and lamivudine. Nucleos. Nucleot. Nucl., 25, 89-107 (2006).
70. Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D. D., Richman, D. D., and Siliciano, R. F., Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 278, 1295-300 (1997).
71. Fischl, M. A., Zidovudine, p. 17-31. In Dolin R, Masur H, and Saag MS (ed),AIDS Therapy. Churchill Livingstone, Philadelphia. (1999).
72. Fish, D. E., Hay, A., Waters, J. A., McGarvey, M. J., Main, J., and Thomas, H. C., Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J. Clin. Pathol., 43, 203-205 (1990).
73. Flexner, C., HIV-protease inhibitors. N. Engl. J. Med., 338, 1281-1292 (1998).
74. Folks, T. M. and Hart, C. E., The life cycle of human immunodeficiency virus type 1, p 29-44. In DeVita Jr VT, Hellman S and Rosenberg SA (ed), AIDS. Lippincott-Raven Publishers, Philadelphia. (1997).
75. Foster, R. H. and Faulds, D., Abacavir. Drugs, 55, 729-736 (1998).
76. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L. Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., and Yu, J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 347, 975-982 (2002).
77. Friedland, G. H., Pollard, R., Griffith, B., Hughes, M., Morse, G., Bassett, R., Freimuth, W., Demeter, L., Connick, E., Nevin, T., Hirsch, M., and Fischl, M., Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3. J. AIDS., 21, 281-292 (1999).
78. Friis-Moller, N., Sabin, C. A., Weber, R., d'Arminio Monforte, A., El-Sadr, W. M., Reiss, P., Thiebaut, R., Morfeldt, L., De Wit, S., Pradier, C., Calvo, G., Law, M. G., Kirk, O., Phillips, A. N., and Lundgren, J. D., Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med., 349, 1993-2003 (2003).
79. Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., Toole, J. J., and Cheng, A. K., Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med., 354, 251-260 (2006).
80. Gallant, J. E. and Deresinski, S., Tenofovir disoproxil fumarate. Clin. Infect. Dis., 37, 944-950 (2003).
81. Gallant, J. E., Rodriguez, A. E., Weinberg, W. G., Young, B., Berger, D. S., Lim, M. L., Liao, Q., Ross, L,. Johnson, J., and Shaefer, M. S., ESS30009 Study. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis., 192, 1921-1930 (2005).
82. Gallant, J. E., Staszewski, S., Pozniak, A. L., DeJesus, E., Suleiman, J. M., Miller, M. D., Coakley, D. F., Lu, B., Toole, J. J., and Cheng, A. K., 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA., 292, 191-201 (2004).
83. Gao, H. Q., Boyer, P. L., Sarafianos, S. G., Arnold, E., and Hughes, S. H., The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J. Molec. Biol., 300, 403-418 (2000).
84. Garcia, P. M., Kalish, L. A., Pitt, J., Minkoff, H., Quinn, T. C., Burchett, S. K., Kornegay, J., Jackson, B., Moye, J., Hanson, C., Zorrilla, C., and Lew, J. F., Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N. Engl. J. Med., 341, 394-402 (1999).
85. Garcia-Samaniego, J., Rodriguez, M., Berenguer, J., Rodriguez-Rosado, R., Carbo, J., Asensi, V., and Soriano, V., Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am. J. Gastroenterol., 96, 179-183 (2001).
86. Gathe, J. C. Jr., Ive, P., Wood, R., Schurmann, D., Bellos, N. C., DeJesus, E., Gladysz, A., Garris, C., and Yeo, J., SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS., 18, 1529-1537 (2004).
87. Gerberding, J. L., Prophylaxis for occupational exposure to HIV. Ann. Intern. Med., 125, 497-501 (1996).
88. Gerard, Y., Maulin, L., Yazdanpanah, Y., De La Tribonniere, X., Amiel, C., Maurage, C. A., Robin, S., Sablonniere, B., Dhennain, C., and Mouton, Y., Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS., 14, 2723-2730 (2000).
89. th International Congress on Drug Therapy in HIV Infection (Glasgow). London: Lippincott Williams & Wilkins, (2002).
90. th European Conference on Clinical aspects and Treatment of HIV Infection. Athens (2001).
91. Greub, G., Ledergerber, B., Battegay, M., Grob, P., Perrin, L., Furrer, H., Burgisser, P., Erb, P., Boggian, K., Piffaretti, J. C., Hirschel, B., Janin, P., Francioli, P., Flepp, M., and Telenti A., Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet., 356, 1800-1805 (2000).
92. Grinspoon, S. and Carr, A., Cardiovascular risk and body-fat abnormalities in HIV infected adults. N. Engl. J. Med., 352, 48-62 (2005).
93. Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., Emini, E. A., and Chodakewitz, J. A., Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med., 337, 734-739 (1997).
94. Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Jonas, L., Meibohm, A., Holder, D., Schleif, W. A., Condra, J. H., Emini, E. A., Isaacs, R., Chodakewitz, J. A., and Richman, D. D., Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. JAMA., 280, 35-41 (1998).
95. Gulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K. E., Meyer, W. A. 3rd., Acosta, E. P., Schackman. B. R., Pilcher. C. D., Murphy, R. L., Maher, W. E., Witt, M. D., Reichman, R. C., Snyder, S., Klingman, K. L., and Kuritzkes, D. R., AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med., 350, 1850-1861 (2004).
96. Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., Chodakewitz, J. A., and Fischl, M. A., A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med., 337, 725-733 (1997).
97. Hanna, G. J. and Hirsch, M. S., New Drugs in Development p. 263-272 In Dolin R, Masur H, and Saag MS (ed), AIDS Therapy. Churchill Livingstone, Philadelphia. (2003).
98. Haubrich, R. H., Kemper, C. A., Hellmann, N. S., Keiser, P. H., Witt, M. D., Tilles, J. G., Forthal, D. N., Leedom, J., Leibowitz, M., McCutchan, J. A., Richman, D. D., and the California Collaborative Treatment Group. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS., 19, 295-302 (2005).
99. Havlir, D. V., Marschner, I. C., Hirsch, M. S., Collier, A. C., Tebas, P., Bassett, R. L., Ioannidis, J. P. A., Holohan, M. K., Leavitt, R., Boone, G., Richman, D. D., Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N. Engl. J. Med., 339, 1261-1268 (1998).
100. Havlir, D. V. and O'Marro, S. D., Atazanavir: New Option for Treatment of HIV Infection. Clin. Infect. Dis., 38, 1599-1604 (2004).
101. Hecht, F. M., Grant, R. M., Petropoulos, C. J., Dillon, B., Chesney, M. A., Tian, H., Hellmann, N. S., Bandrapalli, N. I., Digilio, L., Branson, B., and Kahn, J. O., Brief Report: Sexual Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors N. Engl. J. Med., 339, 307-311 (1998).
102. Hewitt, R. G., Abacavir hypersensitivity reaction. Clin. Infect. Dis., 34, 1137-1142 (2002).
103. Hilts, A. E. and Fish, D. N., Dosage adjustment of antiretroviral agents in patients with organ dysfunction. Am. J. Health-Syst. Pharm., 55, 2528-2533 (1998).
104. Hinrichsen, H., Benhamou, Y., Wedemeyer, H., Reiser, M., Sentjens, R. E., Calleja, J. L., Forns, X., Erhardt, A., Cronlein, J., Chaves, R. L., Yong, C. L., Nehmiz, G., and Steinmann, G. G., Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterol., 127, 1347-1355 (2004).
105. Hirsch, M. S., Azidothymidine. J. Inf. Dis., 157, 427-430 (1998).
106. Hirsch, M. S., Brun-Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D'Aquila, R. T., Demeter, L. M., Hammer, S. M., Johnson, V. A., Loveday, C., Mellors, J. W., Jacobsen, D. M., and Richman, D. D., Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis., 37, 113-128 (2003).
107. Hoff, J., Bani-Sadr, F., Gassin, M., and Raffi, F., Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin. Infect. Dis., 32, 963-969 (2001).
108. Hoffman-LaRoche, Inc. Roferon-A Package Insert. (2001).
109. Hoofnagle, J. H., and Di Bisceglie, A. M., Drug Therapy: The Treatment of Chronic Viral Hepatitis. N. Engl. J. Med., 336, 347-356 (1997).
110. Hughes, M. D., Johnson, V. A., Hirsch, M. S., Bremer, J. W., Elbeik T., Erice, A., Kuritzkes, D. R., Scott, W. A., Spector, S. A., Basgoz, N., Fischl, M. A., and D'Aquila, R. T., Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann. Intern. Med., 126, 929-938 (1997).
111. Hurst, M. and Noble, S., Stavudine: an update of its use in the treatment of HIV infection. Drugs, 58, 919-949 (1998).
112. Imhof, A., Ledergerber, B., Gunthard, H. F., Haupts, S., and Weber, R., Swiss HIV Cohort Study. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? Clin. Infect. Dis., 41, 721-728 (2005).
113. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. A meta-analysis of 15 prospective cohort studies. N. Engl. J. Med., 340, 977-987 (1999).
114. Ioannidis, J. P. A., Abrams, E. J., Ammann, A., Bulterys, M., Goedert, J. J., Gray, L., Korber, B. T., Mayaux, M. J., Mofenson, L. M., Newell, M. L., Shapiro, D. E., Teglas, J. P., and Wilfert, C. M., Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J. Infect. Dis., 183, 539-545 (2001).
115. Iversen, A. K., Shafer, R. W., Wehrly, K., Winters, M. A., Mullins, J. I., Chesebro, B., and Merigan, T. C., Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol., 70, 1086-1090 (1996).
116. Japour, A., Lertora, J., Meehan, P. M., Erice, A., Connor, J. D., Griggith, B. P., Clax, P. A., Holden-Wiltse, J., Hussey, S., Walesky, M., Cooney, E., Pollard, R., Timpone, J., McLaren, C., Johanneson, N., Wood, K., Booth, D., Bassiakos, Y., and Crumpacker, C. S., A phase I study on the safety, pharmacokinetics and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease (ACTG 231 protocol). JAIDS., 13, 235-246 (1996).
117. Jarvis, B. and Faulds, D., Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs., 56, 147-167 (1998).
118. Joint United Nations Programme on HIV/AIDS (UNAIDS), and World Health Organization (WHO). Global Summary of the AIDS Epidemic. AIDS epidemic update: December 2005, 1-2 (2005).
119. Jourdain, G., Ngo-Giang-Huong, N., LeCour, S., Bowonwatanuwong, C., Kantipong, P., Leechanachai, P., Ariyadej, S., Leenasirimakul, P., Hammer, S., Lallemant, M., and the Perinatal HIV Prevention Trial Group. Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy. N. Engl. J. Med., 351, 229-240 (2004).
120. Kakuda, T. and Brinkman, K., Mitochondrial toxic effects of ribavirin. Lancet., 357, 1802-1803 (2001).
121. Katlama, C., Berger, D., Bellos, N., Grinsztejn, B., Haubrich, R., Wilkin, T., Monlina, J. M., Steinhart, C., Pedro, R., de Bethune, M. P., De Meyer, S., Hoetelmans, R., Parys, W., Vangeneuden, T., and Lefebvre, E., Efficacy of TMC114/r in 3 class experienced patients with limited treatment options: 24 week planned interim analysis of 2 96 week multinational dose-finding trials. Abstract 164LB Conference on Retroviruses and Opportunistic Infections, Boston, MA. U.S.A. (2005).
122. Katner, H. P., Paar, D. P., Nadler, J. P., Jensen, E. H., Wilson, H. M., Finn, T. S., Petruschke, R. A., and Zeldin, R. K., Openlabel study of a twice-daily indinavir 800-mg/ritonavir 200 mg regimen in HIV-infected adults failing a protease inhibitor regimen. J. AIDS., 483-487 (2002).
123. Karrer, U., Ledergerber, B., Furrer, H., Elzi, L,. Battegay, M., Cavassini, M., Gayet-Ageron, A., Hirschel, B., Schmid, P., Russotti, M., Weber, R., and Speck, R. F., Swiss HIV Cohort Study. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS., 19, 1987-1994 (2005).
124. Katlama, C. and Havlir, D. V., Newer nucleosides: lamivudine and stavudine. AIDS., 10, (supple A), S135-S143 (1996).
125. Kearney, B. P., Mittan, A., Sayre, J., Flaherty, J. F., Zhong, L., Toole, J. J., and Cheng, A. K., Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir. Abstract A-1617. ICAAC September 2003 Chicago Ill.
126. Kearney, B. P., Flaherty, J. F., and Shah, J., Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharm., 43, 595-612 (2004).
127. Kempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., McDonald, E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., Sun, E., Pizzuti, D., Plattner, J. J., Norbeck, D. W., and Leonard, J. M., Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents. Chemother., 41, 654-660 (1997).
128. Keswani, S. C., Pardo, C. A., Cherry, C. L., Hoke, A. and McArthur, J. C., HIV-associated sensory neuropathies. AIDS., 16, 2105-2117 (2002).
129. Kilby, J. M., Inhibitors of HIV attachment and fusion. P. 252-262. In Dolin R, Masur H, and Saag MS (ed),AIDS Therapy. Churchill Livingstone, Philadelphia. (1999).
130. Kilby, J. M. and Eron, J. J., Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med., 348, 2228-2238 (2003).
131. Kilby, J. M., Sfakianos, G., Gizzi, N., Siemon-Hryczyk, P., Ehrensing, E., Oo, C., Buss, N., and Saag, M. S. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother., 44, 2672-2678 (2000).
132. Kohlbrenner, V. M., Development of a tipranavir mutation score: analysis of protease mutations associated with phenotypic drug susceptibility and antiviral response in Phase II clinical trials. XIII International HIV Drug Resistance Workshop. Tenerife, Spain. (2004).
133. Kosalaraksa, P., Kavlick, M. F., Maroun, V., Le R., and Mitsuya, H., Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J. Virol., 73, 5356-5363 (1999).
134. Knudtson, E., Para, M., Boswell, H., and Fan-Havard, P., Drug Rash with Eosinophilia and Systemic Symptoms Syndrome and Renal Toxicity with a Nevirapine-Containing Regimen in a Pregnant Patient with Human Immunodeficiency Virus. Obstet. Gynecol., 101, 1094-1097 (2003).
135. Konopnicki, D., Mocroft, A., de Wit, S., Antunes, F., Ledergerber, B., Katlama, C., Zilmer, K., Vella, S., Kirk, O., Lundgren, J. D., and the EuroSIDA Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS., 19, 593-601 (2005).
136. Kuhn, L., Abrams, E. J., Matheson, P. B., Thomas, P. A., Lambert, G., Bamji, M., Greenberg, B., Steketee, R. W., Thea, D. M., for the New York City Perinatal HIV Transmission Collaborative Study Group. Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. AIDS., 11, 429-435 (1997).
137. Kurowski, M., Kaeser, B., Sawyer, A., Popescu, M., and Mrozikiewicz, A., Low-dose ritonavir moderately enhances nelfinavir exposure. Clin. Pharmacol. Ther., 72, 123-132 (2002).
138. Lafeuillade, A., Hittinger, G., and Chapadaud, S., Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet., 357, 280-281 (2001).
139. Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S., Piliero, P. J.. Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J. Jr., Chung, J., DeMasi, R., Donatacci, L., Drobnes, C., Delehanty, J., and Salgo, M., TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med., 348, 2175-2185 (2003).
140. Lallemant, M., Jourdain, G., LeCoeur, S., Mary, J. Y., NgoGiang-Huong, N., Koetsawang, S., Kanshana, S., McIntosh, K., Thaineua, V., and the Perinatal HIV Prevention Trial (Thailand) Investigators. Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother-to-Child Transmission of HIV-1 in Thailand. N. Engl. J. Med., 351, 217-228 (2004).
141. Landau, A., Batisse, D., Piketty, C., Jian, R., and Kazatchkin, M., Lack of interference between ribavirin and nucleoside analogues in HIV/HCV coinfected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS., 14, 1857-1858 (2000).
142. Larder, B. A., and Kemp, S. D., Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science, 246, 1155-1158 (1989).
143. Larder, B. A., Kemp, S. D., and Harrigan, P. R., Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science., 269, 696-699 (1995).
144. Lauer, G. M. and Walker, B. D., Hepatitis C Virus Infection. N. Engl. J. Med., 345, 41-52 (2001).
145. Lawrence, J., Mayers, D. L., Hullsiek, K. H., Collins, G., Abrams, D. I., Reisler, R. B., Crane, L. R., Schmetter, B. S., Dionne, T. J., Saldanha, J. M., Jones, M. C., and Baxter, J. D., 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N. Engl. J. Med., 349, 837-846 (2003).
146. Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arasteh, K., Nelson, M., Katlama, C., Stellbrink, H. J., Delfraissy, J. F., Lange, J., Huson, L., DeMasi, R., Wat, C., Delehanty, J., Drobnes, C., and Salgo, M., TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med., 348, 2186-2195 (2003).
147. Ledergerber, B., Egger, M., Erard, V., Weber, R., Hirschel, B., Furrer, H., Battegay, M., Vernazza, P., Bernasconi, E., Opravil, M., Kaufmann, D., Sudre, P., Francioli, P., and Telenti, A., AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. JAMA., 282, 2220-2226 (1999).
148. Lee, W. M., Medical Progress: Hepatitis B Virus Infection. N. Engl. J. Med., 337, 1733-1745 (1997).
149. Le Tiec, C., Barrail, A., Goujard, C., and Taburet, A. M., Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet., 44, 1035-50 (2005).
150. Levine, S., Hernandez, D., Yamanaka, G., Zhang, S., Rose, R., Weinheimer, S., and Colonno, R. J., Efficacies of Entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents. Chemother., 46, 2525-2532 (2002).
151. Lisziewicz, J., Rosenberg, E., Lieberman, J., Jessen, H., Lopalco, L., Siliciano, R., Walker, B., and Lori, F., Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med., 340, 1683-1684 (1999).
152. Little, S. J., Holte, S., Routy, J.-P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., Kilby, M., Wang, L., Whitcomb, J. M., Hellmann, N. S., and Richman, D. D., Antiretroviral-Drug Resistance among Patients Recently Infected with HIV. N. Engl. J. Med., 347, 385-394 (2002a).
153. th Conference on Retroviruses and Opportunistic Infections. Abstract 95. (2002b).
154. Lurie, P., Miller, S., Hecht, F., Chesney, M., and Lo, B., Postexposure prophylaxis after nonoccupational HIV exposure. JAMA., 280, 1769-1773 (1998).
155. McDowell, J. A., Chittick, G. E., Ravitch, J. R., Polk, R. E., Kerkering, T. M., and Stein, D. S., Pharmacokinetics of abacavir, a human immunodeficiency virus type 1 reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents. Chemother., 43, 2855-2861 (1999).
156. McMahon, B. J., Epidemiology and natural history of hepatitis B. Sem. Liver. Disease., 1 (25 Suppl), 3-8 (2005).
157. Maitland, D., Moyle, G., Hand, J., Mandalia, S., Boffito, M., Nelson, M., and Gazzard, B., Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS. 19, 1183-1188 (2005)
158. Malik, A., Abraham, P., and Malik, N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment - case report and review of literature. J. Infect. 51, E61-65 (2005)
159. Marcelin, A. G., Delaugerre, C., Wirden, M., Viegas, P., Simon, A., Katlama, C., and Calvez, V., Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J. Med. Virol., 72, 162-165 (2004).
160. Marcellin, P., Asselah, T., and Boyer, N., Treatment of chronic hepatitis B. J. Viral. Hepatit., 12, 333-345 (2005).
161. Marrone, A., Zampino, R., Karayannis, P., Cirillo, G., Cesaro, G., Guerrera, B., Ricciotti, R., del Giudice, E. M., Utili, R., Adinolfi, L. E., and Ruggiero, G., Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis. Aliment. Pharm. Therap., 22, 707-714 (2005).
162. Martin, A., Smith, D. E., Carr, A., Ringland, C., Amin, J., Emery, S., Hoy, J., Workman, C., Doong, N., Freund, J., and Cooper, D. A., Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS., 18, 1029-1036 (2004).
163. Martinez, E., Arnaiz, J. A., Podzamczer, D., Dalmau, D., Ribera, E., Domingo, P., Knobel, H., Riera, M., Pedrol, E., Force, L., Llibre, J. M., Segura, F., Richart, C., Cortes, C., Javaloyas, M., Aranda, M., Cruceta, A., de Lazzari, E., and Gatell, J. M., Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N. Engl. J. Med., 349, 1036-1046 (2003).
164. Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., Phair, J. P., and Rinaldo, C. R., Plasma viral load and CD4+ Lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med., 126:946-954 (1997).
165. Mellors, J. W., Rinaldo, C. R., Gupta, P., White, R. M., Todd, J. A. and Kingsley, L. A., Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 272, 1167-1170 (1996).
166. Menzo, S., Castagna, A., Monachetti, A., Hasson, H., Danise, A., Carini, E., Bagnarelli, P., Lazzarin, A., and Clementi, M., Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob. Agents. Chemother., 48, 3253-3259 (2004).
167. Meynard, J. L., Vray, M., Morand-Joubert, L., Race, E., Descamps, D., Peytavin, G., Matheron, S., Lamotte, C., Guiramand, S., Costagliola, D., Brun-Vezinet, F., Clavel, F., Girard, P. M., and the Narval Trial Group. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS., 16, 727-736 (2002).
168. Miller, V., Mocroft, A., Reiss, P., Katlama, C., Papadopoulos, A. I., Katzenstein, T., Van Lunzen, J., Antunes, F., Phillips, A. N., and Lundgren, J. D., Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann. Intern. Med., 130, 570-577 (1999).
169. Miller, V., Staszewski, S., Boucher, C. A., and Phair, J. P., Clinical experience with non-nucleoside reverse transcriptase inhibitors. AIDS., 11, (suppl A), S157-S164 (1997).
170. Minkoff, H. and Augenbraun, M., Antiretroviral therapy for pregnant women. Am. J. Obstet. Gynecol., 176, 478-489 (1997).
171. Mock, P. A., Shaffer, N., Bhadrakom, C., Siriwasin, W., Chotpitayasunondh, T., Chearskul, S., Young, N. L., Roongpisuthipong, A., Chinayon, P., Kalish, M. L., Parekh, B., and Mastro, T. D., Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. AIDS., 13, 407-414 (1999).
172. Mocroft, A., Youle, M., Phillips, A. N., Halai, R., Easterbrook, P., Johnson, M. A. and Gazzard, B., The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Arch. Intern. Med., 158, 491-497 (1998).
173. Mofenson, L. M., Lambert, J. S., Stiehm, E. R., Bethel, J., Meyer, W. A., Whitehouse, J., Moye J., Reichelderfer, P., Harris, D. R., Fowler, M. G., Mathieson, B. J., and Nemo, G. J., Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N. Engl. J. Med., 341, 385-393 (1999).
174. Mofenson, L. M. and the U.S. Public Health Service Task Force Recommendations for Use - of Antiretroviral Drugs in Pregnant HIV-1 - Infected Women for Maternal Health and Interventions To Reduce Perinatal HIV-1 Transmission in the United States. MMWR., 51 (RR18), 1-38 (2002).
175. Molto, J., Ruiz, L., Romeu, J., Martinez-Picado, J., Negredo, E., Tural, C., Sirera, G., and Clotet, B., Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. AIDS Res. & Hum. Retrovir., 20, 1283-1288 (2004).
176. Monga, H. K., Rodriguez-Barradas, M. C., Breaux, K., Khattak, K., Troisi, C. L., Velez, M., and Yoffe, B., Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin. Infect. Dis., 33, 240-247 (2001).
177. Montaner, J. S. G., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., Wainberg, M. A., Smith, D., Robinson, P., Hall, D., Myers, M., and Lange, J. M. A., A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA., 279, 930-937 (1998).
178. MMWR. Incidence of Acute Hepatitis B - United States, 1990-2002. MMWR., 51, 1252-1254 (2004).
179. Morsica, G., De Bona, A., Uberti, C., Sitia, G., Finazzi, R., and Lazzarin, A., Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. AIDS., 14, 1656-1658 (2000).
180. Moyle, G., Pozniak, A., Opravil, M., Clumeck, N., DelFraissy, J. -F., Johnson, M., Pelgrom, J., Reynes, J., Vittecoq, D., DeLora, P., Salgo, M., and Duff, F., The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. J. AIDS., 23, 128-137 (2000).
181. nd Interscience on Conference on Antimicrobial Agents and Chemotherapy (San Diego). (2002).
182. Murphy, R. L., Gulick, R. M., DeGruttola, V., D'Aquila, R. T., Eron, J. J., Sommadossi, J. -P., Currier, J. S., Smeaton, L., Frank, I., Caliendo, A. M., Gerber, J. G., Tung, R., and Kuritzkes, D. R., Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J. Infect. Dis., 179, 808-816 (1999).
183. Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., and Miller, A. H., Paroxetine for the Prevention of Depression Induced by High-Dose Interferon Alfa. N. Engl. J. Med., 344, 961-966 (2001).
184. Nduati, R., Grace, J., Mbori-Ngacha, D., Richardson, B., Overbaugh, J., Mwatha, A., Ndinya-Achola, J., Bwayo, J., Onyango, F. E., Hughes, J., and Kreiss, J., Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomised clinical trial. JAMA., 283, 1167-1174 (2000).
185. Nottermans, D. W., Pakker, N. G., Hamann, D., Foudraine, N. A., Kauffmann, R. H., Meenhorst, P. L., Goudsmit, J., Roos, M. T. L., Schellekens, P. T. A., Miedema, F., and Danner, S. A., Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J. Infect. Dis., 180, 1050-1056 (1999).
186. Núñez, M., Puoti, M., Camino, N., and Soriano, V., Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. Clin. Infect. Dis., 37, 1678-1685 (2003).
187. th ICAAC, Abstract V-1148 (2004).
188. O'Brien, W. A., Hartigan, P. M., Daar, E. S., Simberkoff, M. S., and Hamilton, J. D., Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann. Intern. Med., 126, 939-945 (1997).
189. Pachl, C., Todd, J. A., and Kern, D. G., Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J. AIDS., 8, 446-454 (1995).
190. Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., and Holmberg, S. D., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med., 338, 853-60 (1998).
191. Department of Health and Human Services. Panel on clinical practices for the treatment of HIV infection-Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. (2005).
192. Panlilio, A. L., Cardo, D. M. Grohskopf, L. A., Heneine, W., and Ross, C. S., Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis. MMWR., 54 (RR09), 1-17 (2005).
193. Perrillo, R. P., Regenstein, F. G., and Roodman, S. T., Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann. Intern. Med., 105, 382-3 (1986).
194. Perry, C. M. and Faulds, D., Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs, 53, 657-680 (1997).
195. Perry, C. M. and Noble, S., Didanosine: An updated review of its use in HIV infection. Drugs, 58, 1099-1135 (1999).
196. Pesce, A., Taillan, B., and Rosenthal, E., Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet., 341, 1597 (1993).
197. Pialoux, G., Raffi, F., Brun-Vezinet, F., Meiffredy, V., Flandre, P., Gastaut, J. A., Dellamonica, P., Yeni, P., Delfraissy, J. F., and Aboulker, J. P., A randomized trial of three maintenance regiments given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N. Engl. J. Med., 339, 1269-1276 (1998).
198. Picard, V., Angelini, E., Maillard, A., Race, E., Clavel, F., Chene, G., Ferchal, F., and Molina, J. M., Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J. Infect. Dis., 184, 781-784 (2001).
199. Piroth, L., Duong, M., Quantin, C., Abrahamowicz, M., Michardiere, R., Aho, L. S., Grappin, M., Buisson, M., Waldner, A., Portier, H., and Chavanet, P., Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS., 12, 381-388 (1998).
200. Piscitelli, S. C. and Gallicano, K. D., Interactions among drugs for HIV and opportunistic infections. N. Engl. J. Med., 344, 984-996 (2001).
201. Piwoz, E. G., Ross, J., and Humphrey, J., Human immunodeficiency virus transmission during breastfeeding: knowledge, gaps, and challenges for the future. Adv. Exp. Med. Biol., 554, 195-210 (2004).
202. Pollard, R. B., Robinson, P., and Dransfield, K., Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin. Therap., 20, 1071-1092 (1998).
203. Pomerantz, R. J., How HIV Resists Eradication. Hosp. Pract., 87-101 (1998).
204. Pramoolsinsup, C., Management of viral hepatitis B. J. Gastroen. Hepatol., 17, S125-S145 (2002).
205. Preston, D. B., Poiesz, B. J., and Loeb, L. A., Fidelity of HIV-1 reverse transcriptase. Science, 242, 1168-1171 (1998).
206. Public Health Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR., 47(RR-2) 1-30 (1998).
207. Public Health Service Task Force. Recommendations for Use of Antiretroviral drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. MMWR., 47 (RR-2) 1-55 (2005).
208. Quaranta, J. F., Delaney, S. R., Alleman, S., Cassuto, J. P., Dellamonica, P., and Allain, J. P., Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort). J. Med. Virol., 42, 29-32 (1994).
209. Quinn, T. C., Wawer, M. J., Sewankambo, N., Serwadda, D., Li C., Wabwire-Mangen, F., Meehan, M. O., Lutalo, T., and Gray R. H., Viral load and heterosexual transmission of immunodeficiency virus type 1. N. Engl. J. Med., 342, 921-929 (2000).
210. Rana, K. Z. and Dudley, M. N., Clinical pharmacokinetics of stavudine. Clin. Pharmacokinet., 33, 276-284 (1997).
211. Resch, W., Parkin, N., Stuelke, E. L., Watkins, T., and Swanstrom, R., A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. P. Natl. Acad. Sci. U.S.A., 98, 176-181 (2001).
212. Rodriguez-French, A., Boghossian, J., Gray, G. E,. Nadler, J. P., Quinones, A. R., Sepulveda, G. E., Millard, J. M., and Wannamaker, P. G., The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J. AIDS., 35, 22-32 (2004).
213. Ristig, M. B., Crippin, J., Aberg, J. A., Powderly, W. G., Lisker-Melman, M., Kessels, L., and Tebas, P., Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J. Infect. Dis., 186, 1844-1847 (2002).
214. Roberts, J. D., Bebenek, K., and Kunkel, T. A., The accuracy of reverse transcriptase from HIV-1. Science, 242, 1171-1173 (1998).
215. Rockstroh, J. K., Mocroft, A., Soriano, V., Tural, C., Losso, M. H., Horban, A., Kirk, O., Phillips, A., Ledergerber, B., Lundgren, J., and the EuroSIDA Study Group. Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy. J. Infect. Dis., 192, 992-1002 (2005).
216. Rodriguez, M., Berenguer, J., Rodriguez-Rosado, R., Carbo, J., Asensi, V., and Soriano, V., Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am. J. Gastroenterol., 96, 179-183 (2001).
217. Saag, M. S., Emtricitabine, a new antiretroviral agent with activity against HIV and Hepatitis B Virus. Clin. Infect. Dis., 42, 126-131 (2006).
218. Saag, M. S., Holodniy, M., Kuritzkes, D. R., O'Brien, W. A., Coobs, R., Poscher, M. E., Jacobsen, D. M., Shaw, G. M., Richman, D. D., and Volberding, P. A., HIV viral load markers in clinical practice. Nature. Med., 6, 625-629 (1996).
219. Sabin, C., Staszewski, S., Phillips, A. Rabenau, H., Cozzi Lepri, A., Weidman, E., and Miller, V., Discordant immunological and virological responses to HAART. Abstract 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, U.S.A. (2000).
220. Saksela, K., Stevens, C. E., Rubinstein, P., Taylor, P. E., and Baltimore, D., HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann. Intern. Med., 123, 641-648 (1995).
221. Salmon-Céron, D., Chauvelot-Moachon, L., Abad, S., Silbermann, B., and Sogni, P., Mitochondrial toxic effects and ribavirin. Lancet., 357, 1803-1804 (2001).
222. Samuel, R. and Suh, B., Antiretroviral therapy 2000. Arch. Pharm. Res., 23, 425-437 (2000).
223. Sarisky, R. T., Non-nucleoside inhibitors of the HCV polymerase. J. Anitmicrob. Chemother., 54, 14-16 (2004).
224. Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S. A., Mulder, J., Loveday, C., and Christopherson, C., Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect Dis., 171, 1411-1419 (1995).
225. Scully, C. and Porter, S., HIV topic update: oro-genital transmission of HIV. Oral Dis., 6, 92-98 (2000).
226. Shire, N. J. and Sherman, K. E., Management of HBV/HIV coinfected patients. Seminars in Liver Disease, 25 (Suppl 1), 48-57 (2005).
227. Solomon, R. E., VanRaden, M., Kaslow, R. A., Lyter, D., Visscher, B., Farzadegan, H., and Phair, J., Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection. Am. J. Public Health., 80, 1475-1478 (1990).
228. Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, A., Cacoub, P., Katlama, C., Cargnel, A., Mauss, S., Dieterich, D., Moreno, S., Ferrari, C., Poynard, T., and Rockstroh, J., Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS., 16, 813-828 (2002).
229. Soriano, V., Puoti, M., Sulkowski, M., Mauss, S., Cacoub, P., Cargnel, A., Dieterich, D., Hatzakis, A., and Rockstroh, J., Care of patients with hepatitis C and HIV co-infection. Updated recommendations from the HIV-HCV International Panel. AIDS., 18, 1-12 (2004).
230. Soriano, V., Martin-Carbonero, L., Maida, I., Garcia-Samaniego, J., and Núñez, M., New paradigms in the management of HIV and hepatitis C virus coinfection. Curr. Opin. Infect. Dis., 18, 550-560 (2005).
231. Soto, B., Sanchez-Quijano, A., Rodrigo, L., del Olmo, J. A., Garcia-Bengoechea, M., Hernandez-Quero, J., Rey, C., Abad, M. A., Rodriguez, M., Sales Gilabert, M., Gonzalez F., Miron, P., Caruz, A., Relimpio, F., Torronteras, R., Leal, M., and Lissen, E. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol., 26, 1-5 (1997).
232. Spengler, U., Lichterfeld, M., and Rockstroh, J. K., Antiretroviral drug toxicity - a challenge for the hepatologist? J. Hepatol. 36, 283-294 (2002).
233. Squires, K., Lazzarin, A., Gatell, J. M., Powderly, W. G., Pokrovskiy, V., Delfraissy, J. F., Jemsek, J., Rivero, A., Rozenbaum, W., Schrader, S., Sension, M., Vibhagool, A., Thiry, A., and Giordano, M., Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. AIDS., 36, 1011-1019 (2004).
234. Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., Manion, D. J., and Ruiz, N. M., Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N. Engl. J. Med., 341, 1865-1873 (1999).
235. Steel, H. M., Special presentation on aplaviroc-related hepatotoxicity. Program and abstracts of the European AIDS Clinical Society 10th European AIDS Conference; November 17-20, Dublin, Ireland (2005).
236. Sterling, T. R., Chaisson, R. E., and Moore, R. D., Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity. Clin. Infect. Dis., 36, 812-815 (2003).
237. Sulkowski, M. S., Moore, R. D., Mehta, S. H., Chaisson, R. E., and Thomas, D. L., Hepatitis C and progression of HIV disease. JAMA., 288, 199-206 (2002).
238. Tedaldi, E. M., Baker, R. K., Moorman, A. C., Alzola, C. F., Furhrer, J., McCabe, R. E., Wood, K. C., and Holmberg, S. D., HIV Outpatient Study (HOPS) Investigators. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin. Infect. Dis., 36, 363-367 (2003).
239. Tenney, D. J., Levine, S. M., Rose, R. E., Walsh, A. W., Weinheimer, S. P., Discoto, L., Plym, M., Pokornowski, K., Yu, C. F., Angus, P., Ayres, A., Bartholomeusz, A., Sievert, W., Thompson, G., Warner, N., Locarnini, S., and Colonno, R., J. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents. Chemother., 48, 3498-5307 (2004).
240. Thea, D. M, Steketee, R. W., Pliner, V., Bornschlegel, K., Brown, T., Orloff, S., Matheson, P. B., Abrams, E. J., Bamji, M., Lambert, G., Schoenbaum, E. A., Thomas, P. A., Heagarty, M., and Kalish, M. L., The effect of maternal viral load on the risk of perinatal transmission of HIV-1. AIDS., 11, 437-44 (1997).
241. Thio, C. L., Seaberg, E. C., Skolasky, R., Phair, J., Visscher, B., Munoz, A., and Thomas, D. L., for the Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet., 360, 1921-1926 (2002).
242. Thorne, C. and Newell, M. L., Treatment options for the prevention of mother-to-child transmission of HIV. Cur. Opin. Invest. Drugs., 6, 804-811 (2005).
243. Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-Garcia, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., Sette, H. Jr., Passe, S., De Pamphilis, J., Duff, F., Schrenk, U. M., and Dieterich, D. T., for the APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med., 351, 438-450 (2004).
244. Troisi, C. L., Hollinger, F. B., Hoots, W. K., Contant, C., Gill, J., Ragni, M., Parmley, R., Sexauer, C., Gomperts, E., and Buchanan, G., A multicenter study of viral hepatitis in a United States hemophilic population. Blood, 81, 412-418 (1993).
245. Tuomala, R. E., Shapiro, D. E., Mofenson, L. M., Bryson, Y., Culnane, M., Hughes, M. D., O'Sullivan, M. J., Scott, G., Stek, A. M., Wara, D., and Bulterys, M., Antiretroviral Therapy During Pregnancy and the Risk of an Adverse Outcome. N. Engl. J. Med., 346, 1863-1870 (2002).
246. Tural, C., Ruiz, L., Holtzer, C., Schapiro, J., Viciana, P., Gonzalez, J., Domingo, P., Boucher, C., Rey-Joly, C., and Clotet, B., for the Havana Study Group. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS., 16, 209-218 (2002).
247. UNAIDS/WHO. Report on the Global HIV/AIDS Epidemic. January (2006).
248. US Department of Health and Human Services, HIV/AIDS Treatment and Information Service. Safety and toxicity of individual antiretroviral agents in pregnancy, May 17, 2002. In: Guidelines for the use of antiretroviral agents in HIVinfected adults and adolescents. MMWR., 51(RR7), 1-64 (2002).
249. Van Ameijden, E. J., van den Hoek, J. A., Mientjes, G. H., and Coutinho, R. A., A longitudinal study on the incidence and transmission patters on HIV, HBV and HCV infection among drug users in Amsterdam. Eur. J. Epidemiol., 9, 255-262 (1993).
250. Van Gemen, B., Van Beuningen, R., and Nabbe, A., A one tube quantitative HIV-1 RNA NASBS nucleic acid amplification assay using electrochemiluminescent (ECL) labeled probes. J. Virolog. Method., 49, 157-168 (1994).
251. van Leth, F., Phanuphak, P., Ruxrungtham, K., Baraldi, E., Miller, S., Gazzard, B., Cahn, P., Lalloo, U. G., van der Westhuizen, I. P., Malan, D. R., Johnson, M. A., Santos, B. R., Mulcahy, F., Wood, R., Levi, G. C., Reboredo, G., Squires, K., Cassetti, I., Petit, D., Raffi, F., Katlama, C., Murphy, R. L., Horban, A., Dam, J. P., Hassink, E., van Leeuwen, R., Robinson, P., Wit, F. W., and Lange, J. M. 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet., 363, 1253-1263 (2004).
252. van Heeswijk, R. P., Veldkamp, A. I., Hoetelmans, R. M., Mulder, J. W., Schreij, G., Hsu, A., Lange, J. M., Beijnen, J. H., and Meenhorst, P. L., The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS., 13, F95-99 (1999).
253. Veldkamp, A. I., van Heeswijk, R. P., Mulder, J. W., Meenhorst, P. L., Schreij, G., van der Geest, S., Lange, J. M., Beijnen, J. H., and Hoetelmans, R. M., Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J. AIDS., 27, 344-349 (2001).
254. Vento, S., Di Perri, G., Cruciani, M., Garofano, T., Concia, E., and Bassetti, D., Rapid decline of CD4+ cells after interferon treatment in HIV-1 infection. Lancet., 341, 958-959 (1993).
255. Vlahov, D., Graham, N., Hoover, D., Flynn, C., Bartlett, J. G., Margolick, J. B., Lyles, C. M., Nelson, K., E., Smith, D., Holmberg, S., and Farzadegan, H., Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users- plasma viral load and CD4+ cell count. JAMA., 279, 35-40 (1998).
256. Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., Johnson, D., Lalonde, R., Japour, A., Brun, S., and Sun, E., M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med., 346, 2039-2046 (2002).
257. Watts, D. H., Management of Human Immunodeficiency Virus Infection in Pregnancy. N. Engl. J. Med., 346, 1879-1891 (2002).
258. Weinheimer, S., Discotto, L., Friborg, J., Yang, H., and Colonno, R., Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob. Agent. Chemother., 49, 3816-3824 (2005).
259. White, K. L., Margot, N. A., Ly, J. K., Chen, J. M., Ray, A. S., Pavelko, M., Wang, R., McDermott, M., Swaminathan, S., and Miller, M. D., A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS., 19, 1751-1760 (2005).
260. Winnock, M., Salmon-Céron, D., Dabis, F., and Chêne, G., Interaction between HIV-1 and HCV infections: towards a new entity? J. Antimicrob. Chemother., 53, 936-946 (2004).
261. Wolbach, J. and Capoccia, K., A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection. Nurse Practitioner., 24, 81-92 (1999).
262. Yerly, S., Perneger, T. V., Hirschel, B., Dubuis, O., Matter, L., Malinverni, R., Furrer, H., and Perrin, L., A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. Arch. Intern. Med., 158, 247-252 (1998).
263. Ying, C., De Clercq, E., Nicholson, W., Furman, P., and Neyts, J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J. Viral. Hepat., 7, 161-165 (2000).
264. Young, B., Fischl, M. A., Wilson, H. M., Finn, T. S., Jensen, E. H., DiNubile, M. J., and Zeldin, R. K., Open-label study of a twice-daily indinavir 800-mg/ritonavir 100 mg regimen in protease inhibitor-naive HIV-infected adults. JAIDS., 31, 478-482 (2002).
265. Youle, M., Mocroft, A., and Johnson, M., Lipid profiles in patients on ritonavir/indinavir containing salvage regimens [abstract 24]. Antivir. Ther., 4 (Suppl 2), 22 (1999).
266. Zhang, Y. M., Imamichi, H., Imamichi, T., Lane, H. C., Falloon, J., Vasudevachari, M. B., and Salzman, N. P., Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol., 71, 6662-6670 (1997).